ViroMissile Advances Phase I Cancer Virus Trial to Higher Dose
ViroMissile's safety panel cleared the oncolytic virus therapy IDOV-2 to move to a higher dose after the first cohort passed review.
San Diego-based ViroMissile, Inc. announced Wednesday that an independent Safety Review Committee has cleared its experimental cancer therapy IDOV-2 to advance to the next, higher dose cohort in an ongoing Phase I clinical trial, after finding no disqualifying safety signals in the first group of patients treated.
The trial, registered under NCT06910657, is evaluating IDOV-2 — formerly known as IDOV-Immune — in patients diagnosed with advanced solid tumors. The drug is built on ViroMissile's proprietary IDOV platform, which stands for Intravenously Deliverable Oncolytic Virus, a technology designed to allow cancer-killing viruses to be administered directly into the bloodstream rather than injected locally into tumors.
Read more Sigo Seguros Opens Auto Insurance Sales to AI Chatbots →
The study is a first-in-human Phase I trial, meaning this is the earliest stage at which the therapy is being tested in people, with the primary goal of assessing safety and determining appropriate dosing. Advancing from the first cohort to a higher dose level is a standard milestone in dose-escalation trials and signals that the lowest tested dose did not produce unacceptable adverse effects.
The trial is being conducted across two countries, with sites operating in the United States and in Australia through the company's subsidiary, ViroMissile Australia, PTY, LTD. The international footprint expands the pool of eligible patients and reflects a common strategy among clinical-stage biotechs seeking to accelerate enrollment timelines.
Continue reading at GlobeNewswire - Industry News on Financial Services.
